Where now in the management of renal artery stenosis? Implications of the ASTRAL and CORAL trials

Current Opinion in Nephrology and Hypertension

Volumn 23, Issue 6, 2014, Pages 525-532

  Ritchie, James ^a   Alderson, Helen V ^a   Kalra, Philip A ^a  

^a SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Atherosclerotic renovascular disease; Biomarkers; Flash pulmonary edema; Heart failure; Renal artery stenosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; ENDOTHELIN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OXYGEN; TROPONIN T; BIOLOGICAL MARKER;

ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; END STAGE RENAL DISEASE; ENDOTHELIAL PROGENITOR CELL; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY ARTERY STENOSIS; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; MESENCHYMAL STEM CELL; MICROCIRCULATION; MICROVASCULATURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN BLOOD LEVEL; PHENOTYPE; PRESSURE GRADIENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REVASCULARIZATION; REVIEW; STEM CELL TRANSPLANTATION; THROMBOCYTE ACTIVATION; TREATMENT RESPONSE; ADVERSE EFFECTS; ANGIOPLASTY; ANIMAL; CLINICAL TRIAL (TOPIC); DEVICES; DISEASE MODEL; EVIDENCE BASED MEDICINE; METABOLISM; PATIENT SELECTION; RENAL ARTERY OBSTRUCTION; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STENT; TREATMENT OUTCOME;

ANGIOPLASTY; ANIMALS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; EVIDENCE-BASED MEDICINE; HUMANS; PATIENT SELECTION; RENAL ARTERY OBSTRUCTION; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STENTS; TREATMENT OUTCOME;

EID: 84927590446     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000059     Document Type: Review

References (70)

1. Wheatley K, Ives N, Gray R, et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 2009; 361:1953-1962.
2. Cooper CJ, Murphy TP, Cutlip DE, et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 2014; 370:13-22.
3. White CJ. The 'chicken little' of renal stent trials: the CORAL trial in perspective. JACC Cardiovasc Interv 2014; 7:111-113.
4. Ritchie J, Green D, Chrysochou C, et al. High-risk clinical presentations in atherosclerotic renovascular disease: prognosis and response to renal artery revascularization. Am J Kidney Dis 2014; 63:186-197.
5. Hemmelgarn BR, Zhang J, Manns BJ, et al. Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int 2006; 69:2155-2161.
6. Glassock RJ, Winearls C. Screening for CKD with eGFR: doubts and dangers. Clin J Am Soc Nephrol 2008; 3:1563-1568.
7. Madder RD, Hickman L, Crimmins GM, et al. Validity of estimated glomerular filtration rates for assessment of baseline and serial renal function in patients with atherosclerotic renal artery stenosis: implications for clinical trials of renal revascularization. Circ Cardiovasc Interv 2011; 4:219-225.
8. Crimmins GM, Madder RD, Marinescu V, Safian RD. Validity of estimated glomerular filtration rates for assessment of renal function after renal artery stenting in patients with atherosclerotic renal artery stenosis. JACC Cardiovasc Interv 2014; 7:543-549.
9. Christensen PK, Larsen S, Horn T, et al. Renal function and structure in albuminuric type 2 diabetic patients without retinopathy. Nephrol Dial Transplant 2001; 16:2337-2347.
10. Tsuboi N, Kawamura T, Koike K, et al. Glomerular density in renal biopsy specimens predicts the long-term prognosis of IgA nephropathy. Clin J Am Soc Nephrol 2010; 5:39-44.
11. Cheung CM, Chrysochou C, Shurrab AE, et al. Effects of renal volume and single-kidney glomerular filtration rate on renal functional outcome in atherosclerotic renal artery stenosis. Nephrol Dial Transplant 2010; 25:1133-1140.
12. Lim SW, Chrysochou C, Buckley DL, et al. Prediction and assessment of responses to renal artery revascularization with dynamic contrast-enhanced magnetic resonance imaging: a pilot study. Am J Physiol Renal Physiol 2013; 305:F672-F678.
13. Iliescu R, Fernandez SR, Kelsen S, et al. Role of renal microcirculation in experimental renovascular disease. Nephrol Dial Transplant 2010; 25:1079-1087.
14. Chade AR, Kelsen S. Renal microvascular disease determines the responses to revascularization in experimental renovascular disease. Circ Cardiovasc Interv 2010; 3:376-383.
15. Ramos F, Kotliar C, Alvarez D, et al. Renal function and outcome of PTRA and stenting for atherosclerotic renal artery stenosis. Kidney Int 2003; 63:276-282.
16. Kalra PA, Chrysochou C, Green D, et al. The benefit of renal artery stenting in patients with atheromatous renovascular disease and advanced chronic kidney disease. Cathet Cardiovasc Intervent 2010; 75:1-10.
17. Trani C, Porto I, Tommasino A, et al. Baseline inflammatory status and longterm changes in renal function after percutaneous renal artery stenting: a prospective study. Int J Cardiol 2013; 167:1006-1011.
18. Imanishi M, Akabane S, Takamiya M, et al. Critical degree of renal arterial stenosis that causes hypertension in dogs. Angiology 1992; 43:833-842.
19. Schoenberg SO, Knopp MV, Londy F, et al. Morphologic and functional magnetic resonance imaging of renal artery stenosis: a multireader tricenter study. J Am Soc Nephrol 2002; 13:158-169.
20. Gloviczki ML, Saad A, Textor SC. Blood oxygen level-dependent (BOLD) MRI analysis in atherosclerotic renal artery stenosis. Curr Opin Nephrol Hypertens 2013; 22:519-524. Excellent review of BOLD-MRI.
21. Chrysochou C, Mendichovszky IA, Buckley DL, et al. BOLD imaging: a potential predictive biomarker of renal functional outcome following revascularization in atheromatous renovascular disease. Nephrol Dial Transplant 2012; 27:1013-1019.
22. Saad A, Crane J, Glockner JF, et al. Human renovascular disease: estimating fractional tissue hypoxia to analyze blood oxygen level-dependent MR. Radiology 2013; 268:770-778.
23. Saad A, Herrmann SMS, Crane J, et al. Stent revascularization restores cortical blood flow and reverses tissue hypoxia in atherosclerotic renal artery stenosis but fails to reverse inflammatory pathways or glomerular filtration rate. Circ Cardiovasc Interv 2013; 6:428-435.
24. Gloviczki ML, Keddis MT, Garovic VD, et al. TGF expression and macrophage accumulation in atherosclerotic renal artery stenosis. Clin J Am Soc Nephrol 2013; 8:546-553.
25. Hashemi M. The study of pentoxifylline drug effects on renal apoptosis and BCL-2 gene expression changes following ischemic reperfusion injury in rat. Iran J Pharm Res 2014; 13:181-189.
26. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340:115-126.
27. Imori Y, Akasaka T, Ochiai T, et al. Co-existence of carotid artery disease, renal artery stenosis, and lower extremity peripheral arterial disease in patients with coronary artery disease. Am J Cardiol 2014; 113:30-35.
28. Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008; 118:2243-2251.
29. Hommels MJ, van der Ven AJA, Kroon AA, et al. C-reactive protein, atherosclerosis and kidney function in hypertensive patients. J Hum Hypertens 2005; 19:521-526.
30. Schlager O, Amighi J, Haumer M, et al. Inflammation and adverse cardiovascular outcome in patients with renal artery stenosis and peripheral artery disease. Atherosclerosis 2009; 205:314-318.
31. Khangura KK, Eirin A, Kane GC, et al. Extrarenal atherosclerotic disease blunts renal recovery in patients with renovascular hypertension. J Hypertens 2014; 32:1300-1306.
32. Starke A, Wüthrich RP, Waeckerle-Men Y. TGF-beta treatment modulates PD-L1 and CD40 expression in proximal renal tubular epithelial cells and enhances CD8 cytotoxic T-cell responses. Nephron Exp Nephrol 2007; 107:e22-e29.
33. Li H, Nord EP. IL-8 amplifies CD40/CD154-mediated ICAM-1 production via the CXCR-1 receptor and p38-MAPK pathway in human renal proximal tubule cells. Am J Physiol Renal Physiol 2009; 296:F438-F445.
34. Kairaitis L, Wang Y, Zheng L, et al. Blockade of CD40-CD40 ligand protects against renal injury in chronic proteinuric renal disease. Kidney Int 2003; 64:1265-1272.
35. Haller ST, Kalra PA, Ritchie JP, et al. Effect of CD40 and sCD40L on renal function and survival in patients with renal artery stenosis. Hypertension 2013; 61:894-900.
36. Chrysochou C, Manzoor S, Wright J, et al. Role of renal function and cardiac biomarkers (NT-proBNP and Troponin) in determining mortality and cardiac outcome in atheromatous renovascular disease. Kidney Blood Press Res 2009; 32:373-379.
37. Zhu Q, An N, Bai Y, et al. Prospective monitoring N-terminal pro-brain natriuretic peptide during natural progression of atherosclerotic renal artery stenosis in elderly. Arch Gerontol Geriatr 2013; 56:395-399.
38. Wright JR, Shurrab AE, Cooper A, et al. Progression of cardiac dysfunction in patients with atherosclerotic renovascular disease. QJM 2009; 102:695-704.
39. Silva JA, Chan AW, White CJ, et al. Elevated brain natriuretic peptide predicts blood pressure response after stent revascularization in patients with renal artery stenosis. Circulation 2005; 111:328-333.
40. Staub D, Zeller T, Trenk D, et al. Use of B-type natriuretic peptide to predict blood pressure improvement after percutaneous revascularization for renal artery stenosis. Eur J Vasc Endovasc Surg 2010; 40:599-607.
41. Nowakowska-Fortuna E, Saeed A, Guron G, et al. Brain natriuretic peptides in atherosclerotic renal artery stenosis and effects of renal angioplasty. Kidney Blood Press Res 2013; 37:657-666.
42. Jaff MR, Bates M, Sullivan T, et al. Significant reduction in systolic blood pressure following renal artery stenting in patients with uncontrolled hypertension: results from the HERCULES trial. Catheter Cardiovasc Interv 2012; 80:343-350.
43. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease): summary of recommendations. J Vasc Interv Radiol 2006; 17:1383-1397.
44. Börgel J, Springer S, Ghafoor J, et al. Unrecognized secondary causes of hypertension in patients with hypertensive urgency/emergency: prevalence and co-prevalence. Clin Res Cardiol 2010; 99:499-506.
45. Benjamin MM, Fazel P, Filardo G, et al. Prevalence of and risk factors of renal artery stenosis in patients with resistant hypertension. Am J Cardiol 2014; 113:687-690.
46. Chrysochou C, Kalra PA. Epidemiology and natural history of atherosclerotic renovascular disease. Prog Cardiovasc Dis 2009; 52:184-195.
47. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2006; 28:1462-1536.
48. Chrysochou C, Schmitt M, Siddals K, et al. Reverse cardiac remodelling and renal functional improvement following bilateral renal artery stenting for flash pulmonary edema. Nephrol Dial Transplant 2013; 28:479-483.
49. Protasiewicz M, Kadziela J, Poczatek K, et al. Renal artery stenosis in patients with resistant hypertension. Am J Cardiol 2013; 112:1417-1420.
50. Chade AR. Renal vascular structure and rarefaction. Compr Physiol 2013; 3:817-831.
51. Chade AR, Stewart NJ, Peavy PR. Disparate effects of single endothelin-A and-B receptor blocker therapy on the progression of renal injury in advanced renovascular disease. Kidney Int 2014; 85:833-844.
52. Chade AR, Zhu X, Lavi R, et al. Endothelial progenitor cells restore renal function in chronic experimental renovascular disease. Circulation 2009; 119:547-557.
53. Eirin A, Zhu X-Y, Li Z, et al. Endothelial outgrowth cells shift macrophage phenotype and improve kidney viability in swine renal artery stenosis. Arterioscler Thromb Vasc Biol 2013; 33:1006-1013.
54. Eirin A, Zhu X-Y, Krier JD, et al. Adipose tissue-derived mesenchymal stem cells improve revascularization outcomes to restore renal function in swine atherosclerotic renal artery stenosis. Stem Cells 2012; 30:1030-1041.
55. Wright JR, Shurrab AE, Cooper A, et al. Left ventricular morphology and function in patients with atherosclerotic renovascular disease. J Am Soc Nephrol 2005; 16:2746-2753.
56. Khan AR, Sheikh M, Kaw D, et al. Prevalence and factors associated with left ventricular remodeling in renal artery stenosis. J Am Soc Hypertens 2014; 8:254-261.
57. Zeller T, Rastan A, Schwarzwälder U, et al. Regression of left ventricular hypertrophy following stenting of renal artery stenosis. J Endovasc Ther 2007; 14:189-197.
58. Marcantoni C, Zanoli L, Rastelli S, et al. Effect of renal artery stenting on left ventricular mass: a randomized clinical trial. Am J Kidney Dis 2012; 60:39-46.
59. Green D, Ives N, Handly K, Kalra PA. Changes in cardiac structure and function after revascularization versus medical therapy for renal artery stenosis: the ASTRAL Heart Echocardiography Sub-Study. Atlanta: American Society of Nephrology; 2013. PO1091.
60. Kane GC, Xu N, Mistrik E, et al. Renal artery revascularization improves heart failure control in patients with atherosclerotic renal artery stenosis. Nephrol Dial Transplant 2010; 25:813-820.
61. Hackam DG, Duong-Hua ML, Mamdani M, et al. Angiotensin inhibition in renovascular disease: a population-based cohort study. Am Heart J 2008; 156:549-555.
62. Chrysochou C, Foley RN, Young JF, et al. Dispelling the myth: the use of reninangiotensin blockade in atheromatous renovascular disease. Nephrol Dial Transplant 2012; 27:1403-1409.
63. Cheung CM, Patel A, Shaheen N, et al. The effects of statins on the progression of atherosclerotic renovascular disease. Nephron Clin Pract 2007; 107:c35-c42.
64. Hackam DG, Wu F, Li P, et al. Statins and renovascular disease in the elderly: a population-based cohort study. Eur Heart J 2011; 32:598-610.
65. Cooper CJ, Haller ST, Colyer W, et al. Embolic protection and platelet inhibition during renal artery stenting. Circulation 2008; 117:2752-2760.
66. Duranay M, Kanbay M, Akay H, et al. Nebivolol improves renal function in patients who underwent angioplasty due to renal artery stenosis: a pilot study. Nephron Clin Pract 2010; 114:c213-c217.
67. Ritchie J, Green D, Alderson H, et al. Optimal medical therapy in ARVD. Glasgow: UK Renal Association; 2014; 68.
68. Liang P, Hurks R, Bensley RP, et al. The rise and fall of renal artery angioplasty and stenting in the United States. J Vasc Surg 2013; 58:1331-1338.
69. Safak E, Wilke C, Derer W, et al. Long-term follow-up of patients with atherosclerotic renal artery disease. Am J Hypertens 2013; 7:24-31.
70. Kim SH. Clinical manifestations of fibromuscular dysplasia vary by patient sex: a report of the United States registry for fibromuscular dysplasia. J Am Coll Cardiol 2013; 61:E2053.